Skip to main content
. 2019 Jun 4;39(6):BSR20182366. doi: 10.1042/BSR20182366

Figure 5. miR-27a targets SFRP1 by inhibiting its transcription.

Figure 5

(A) The binding site of miR-27a and SFRP1 predicted by microRNA software. (B) Comparison of luciferase activity in HOS and U2OS cells after treatment with the WT-SFRP1 + miR-27a inhibitor, the MUT-SFRP1 + miR-27a inhibitor, the WT-SFRP1 + control inhibitor and the MUT-SFRP1 + control. WT-SFRP1, SFRP1 wild-type plasmid; MUT-SFRP1, SFRP1 mutant-type; *P<0.05 compared with the MUT-SFRP1 + miR-27a inhibitor, the WT-SFRP1 + control inhibitor and the MUT-SFRP1 + control groups. The measurement data were expressed as mean ± S.D. The comparison among multiple groups was analyzed by one-way ANOVA; the experiment was repeated three times.